

Please amend the subject application as follows.

**In the Specification:**

✓  
Please amend the specification as follows:

✓  
Please replace the paragraph on page 9, at lines 21-25, with the following rewritten paragraph:

N,  
-- Figure 7a is a graph showing the effects of DR7-primed CD4<sup>+</sup>CD45RO<sup>+</sup> T<sub>h</sub> cells on differentiation of B cells into IgM secreting SKW B cells, as described in Example 2, *infra*.

Figure 7b is a graph showing the effects of DR7-primed CD4<sup>+</sup>CD45RO<sup>+</sup> T<sub>h</sub> cells on differentiation of B cells into IgG secreting CESS B cells, as described in Example 2, *infra*. --

✓  
Please replace the paragraph on page 9, at lines 27-30, with the following rewritten paragraph:

N/2  
-- Figure 8a is a graph showing the effect of anti-CD28 and anti-B7 mAbs on the T<sub>h</sub>-induced production of IgM by B cells as described in Example 2, *infra*.

8b  
Figure 8a is a graph showing the effect of anti-CD28 and anti-B7 mAbs on the T<sub>h</sub>-induced production of IgG by B cells as described in Example 2, *infra*. --  
8-28-03

Applicants: Peter S. Linsley et al.  
U.S. Serial No.: 08/219,200  
Filed: March 29, 1994  
Page: 3

✓  
Please replace the paragraph on page 9, at lines 32-35, with the following rewritten paragraph:

N3  
-- Figure 9a is a diagrammatic representation of a B7Ig protein fusion construct as described in Example 3, *infra* (dark shaded regions = oncostatin M; unshaded regions = B7, stippled regions = human Ig Cγ1).

Figure 9b is a diagrammatic representation of a CD28Ig protein fusion construct as described in Example 3, *infra* (dark shaded regions = oncostatin M; unshaded regions = CD28, stippled regions = human Ig Cγ1). --

#### REMARKS

Claims 79-94 are pending and now allowed. Applicants acknowledge that the Patent Office has re-numbered the claims 1-16.

#### Examiner's Amendment:

In items 3 and 4 of the Notice of Allowability, the Examiner proposes an Examiner's Amendment. Applicants accept the Examiner's amendment.

#### Formal drawings:

In item 6 of the Notice of Allowability, the Patent Office states that the formal drawings and photographs that were previously submitted fail to comply with 37 C.F.R. §1.84. Applicants concurrently provide the formal drawings in a separate submission.